相关实验视频
Updated: Feb 13, 2026

03:57
Electrochemotherapy of Tumours
Published on: December 15, 2008
25.1K
研究瘤坏死因子对手对嗅觉的影响
Andreas Espehana1,2, George Macfarlane1, Elizabeth Mairenn Garden1
1Norwich Medical School, University of East Anglia, Norwich, UK.
概括
瘤坏死因子 (TNF) 抗剂可能会改善嗅觉功能,在个体有嗅觉功能障碍. 建议对这组患者进行进一步的研究,以证实这些有前途的发现.
科学领域:
- 免疫学 免疫学 免疫学
- 神经学 神经学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 瘤坏死因子 (TNF) 抗剂是抗炎药物.
- 之前在小鼠模型上的研究表明,TNF抗剂可以改善嗅觉功能.
- 嗅觉功能障碍显著影响生活质量.
研究的目的:
- 研究TNF抗剂对人类嗅觉功能的影响.
- 在患有嗅觉障碍的患者中收集潜在随机对照试验的初步数据.
主要方法:
- 一项前性,单中心队列研究,涉及成人患者开始TNF抗剂治疗 (阿达利姆巴生物类似药).
- 嗅觉功能在基线和3个月后使用扩展的嗅探棒测试进行评估.
- 患者还填写了关于他们的症状的问卷.
主要成果:
- 在TNF抗剂治疗3个月后,没有观察到整体TDI得分的显著改善 (p=0.08).
- 然而,患有基线嗅觉功能障碍的患者 (n=20) 在TDI得分上显示出统计学上显著的改善 (p=0.012).
结论:
- TNF抗剂在患有现有的嗅觉障碍的患者中显示出改善嗅觉功能的潜力.
- 需要对目标患者群体进行进一步的研究,以证实这些发现并探索治疗潜力.
相关概念视频
Olfaction
48.9K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
48.9K
Necrosis
6.7K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.7K
Cholinergic Antagonists: Pharmacokinetics
990
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
990
Cholinergic Antagonists: Therapeutic Uses
1.5K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Transcription Factors
82.9K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.9K
Cholinergic Antagonists: Pharmacological Actions
1.8K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.8K

